Strata Oncology has a total of 46 patents globally, out of which 1 have been granted. Of these 46 patents, more than 67% patents are active. Australia is where Strata Oncology has filed the maximum number of patents, followed by Singapore and Europe (EPO). Parallelly, USA seems to be the main focused R&D centre and also is the origin country of Strata Oncology.
Strata Oncology founded in 2015, is a fast-growing precision oncology company revolutionizing cancer care through advanced molecular profiling and clinical trial integration. Partnering with leading healthcare systems, Strata provides rapid genomic sequencing to match patients with targeted therapies and trials. Their multidisciplinary team is driven by a shared mission to improve outcomes and expand access to personalized cancer treatment.
Do read about some of the most popular patents of Strata Oncology which have been covered by us in this article and also you can find Strata Oncology patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Strata Oncology patent portfolio.
How many patents does Strata Oncology have?
Strata Oncology has a total of 46 patents globally. These patents belong to 7 unique patent families. Out of 46 patents, 31 patents are active.
How Many Patents did Strata Oncology File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Strata Oncology Applications Filed | Strata Oncology Patents Granted |
| 2025 | 3 | – |
| 2024 | 1 | – |
| 2023 | 3 | – |
| 2022 | 31 | – |
| 2020 | – | 1 |
| 2019 | 6 | – |
| 2018 | 2 | – |
How many Strata Oncology patents are Alive/Dead?
Worldwide Patents
How Many Patents did Strata Oncology File in Different Countries?
Countries in which Strata Oncology Filed Patents
| Country | Patents |
| Australia | 6 |
| Singapore | 5 |
| Europe (EPO) | 5 |
| United States of America | 5 |
| Canada | 5 |
| Hong Kong (S.A.R.) | 3 |
| New Zealand | 3 |
| Israel | 3 |
| Mexico | 2 |
| Japan | 2 |
Where are Research Centres of Strata Oncology Patents Located?
The Research Centre for all the Strata Oncology patents is the United States of America.
Strata Oncology Best Patent
WO2019074963A1 is the most popular patent in the Strata Oncology portfolio. It has received 9 citations so far from companies like Zhiben Medical Technology (Shanghai) Co Ltd, Shenzhen Hypros Biotechnology Co Ltd and DIEXOM Co Ltd.
What Percentage of Strata Oncology US Patent Applications were Granted?
Strata Oncology (Excluding its subsidiaries) has filed 5 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 1 have been granted leading to a grant rate of 100.0%.
Below are the key stats of Strata Oncology patent prosecution at the USPTO.
Which Law Firms are managing US Patents for Strata Oncology?
| Law Firm | Total Applications | Success Rate |
| Morse Barnes Brown & Pendleton Pc | 5 | 100.00% |
List of Strata Oncology Patents
| Strata Oncology Patents | Title |
| HK40121019A | Methods Of Determining Cancer Therapy Effectiveness |
| SG11202503318RA | Methods Of Determining Cancer Therapy Effectiveness |
| MX2025005696A | Methods Of Determining Cancer Therapy Effectiveness |
| AU2023383478A1 | Methods Of Determining Cancer Therapy Effectiveness |
| HK40116617A | Cancer Biomarkers For Immune Checkpoint Inhibitors |
| US20240191310A1 | Methods Of Determining Cancer Therapy Effectiveness |
| US20240290422A1 | Methods For Identifying Mutations Using Machine Learning |
| US20240287616A1 | Methods Of Detecting Ntrk Fusion Proteins |
| EP4430214A1 | Cancer Biomarkers For Immune Checkpoint Inhibitors |
| EP4356130A1 | Methods Of Determining Cancer Therapy Effectiveness |
| EP4356319A2 | Methods For Identifying Mutations Using Machine Learning |
| EP4355917A1 | Methods Of Detecting Ntrk Fusion Proteins |
| WO2024108174A3 | Methods Of Determining Cancer Therapy Effectiveness |
| MX2024005612A | Cancer Biomarkers For Immune Checkpoint Inhibitors. |
| SG11202403242XA | Cancer Biomarkers For Immune Checkpoint Inhibitors |
| AU2022381055A1 | Cancer Biomarkers For Immune Checkpoint Inhibitors |
| IL309487A | Methods Of Determining Cancer Therapy Effectiveness |
| IL309485A | Methods Of Detecting Ntrk Fusion Proteins |
| IL309473A | Methods For Identifying Mutations Using Machine Learning |
| SG11202309716VA | Methods For Identifying Mutations Using Machine Learning |
| SG11202309714TA | Methods Of Detecting Ntrk Fusion Proteins |
| SG11202309717WA | Methods Of Determining Cancer Therapy Effectiveness |
| AU2022291938A1 | Methods Of Determining Cancer Therapy Effectiveness |
| AU2022294957A1 | Methods Of Detecting Ntrk Fusion Proteins |
| AU2022292749A1 | Methods For Identifying Mutations Using Machine Learning |
| JP2024540391A | Cancer Biomarkers For Immune Checkpoint Inhibitors |
| WO2023081537A1 | Cancer Biomarkers For Immune Checkpoint Inhibitors |
| WO2022266518A3 | Methods For Identifying Mutations Using Machine Learning |
| CA3224714A1 | Methods Of Detecting Ntrk Fusion Proteins |
| CA3229707A1 | Methods Of Determining Cancer Therapy Effectiveness |
| CA3237909A1 | Cancer Biomarkers For Immune Checkpoint Inhibitors |
| US20220081724A1 | Methods Of Detecting And Treating Subjects With Checkpoint Inhibitor-Responsive Cancer |
| EP3899537A4 | Methods Of Detecting And Treating Subjects With Checkpoint Inhibitor-Responsive Cancer |
| WO2022266551A1 | Methods Of Detecting Ntrk Fusion Proteins |
| WO2022266552A1 | Methods Of Determining Cancer Therapy Effectiveness |
| CA3224548A1 | Methods For Identifying Mutations Using Machine Learning |
| NZ806867A | Methods Of Determining Cancer Therapy Effectiveness |
| NZ806857A | Methods Of Detecting Ntrk Fusion Proteins |
| NZ806851A | Methods For Identifying Mutations Using Machine Learning |
| HK40061090A | Methods Of Detecting And Treating Subjects With Checkpoint Inhibitor-Responsive Cancer |
| JP2022514952A5 | Methods Of Detecting And Treating Subjects With Checkpoint Inhibitor Responsive Cancers |
| AU2019403339A1 | Methods Of Detecting And Treating Subjects With Checkpoint Inhibitor-Responsive Cancer |
| US10699802B2 | Microsatellite Instability Characterization |
| WO2020132363A1 | Methods Of Detecting And Treating Subjects With Checkpoint Inhibitor-Responsive Cancer |
| CA3124471A1 | Methods Of Detecting And Treating Subjects With Checkpoint Inhibitor-Responsive Cancer |
| WO2019074963A1 | Microsatellite Instability Characterization |
What are Strata Oncology key innovation segments?
What Technologies are Covered by Strata Oncology?
The chart below distributes patents filed by Strata Oncology in different countries on the basis of the technology protected in patents. It also represents the markets where Strata Oncology thinks it’s important to protect particular technological inventions.
R&D Focus: How has Strata Oncology search focus changed over the years?
EXCLUSIVE INSIGHTS COMING SOON!
Interested in knowing about the areas of innovation that are being protected by Strata Oncology?
